On Tuesday, Hoth Therapeutics, Inc. HOTH shared interim security and efficacy outcomes from its Part 2a medical trial of HT-001, designed to deal with pores and skin toxicities linked to Epidermal Progress Issue Receptor Inhibitors in most cancers sufferers.
Knowledge from the open-label portion of the CLEER-001 trial demonstrated:
- 100% of sufferers achieved the first efficacy endpoint of an ARIGA rating ≤1, exhibiting important pores and skin toxicity enchancment by the six-week mark.
- 66% of sufferers reported lowered ache and itching scores, additional enhancing high quality of life.
All sufferers maintained their full EGFRi dosage, preserving the most cancers remedy’s full therapeutic impact—a notable enchancment in comparison with previous stories exhibiting widespread dose reductions or remedy halts because of skin-related unwanted side effects.
The trial makes use of the proprietary Acneiform Rash Investigator World Evaluation Scale, developed in collaboration with onco-dermatology specialists. The size ensures exact measurement and evaluation of pores and skin toxicity enhancements.
Robb Knie, CEO of Hoth Therapeutics, stated, “These outcomes are a big milestone, underscoring HT-001’s potential to remodel affected person care by mitigating debilitating pores and skin toxicities whereas sustaining essential most cancers therapies. Our knowledge spotlight HT-001’s robust security profile and the potential for it to set a brand new normal of care on this underserved space.”
No treatment-related antagonistic results have been reported, reaffirming HT-001’s glorious tolerability.
“These interim findings align with a current case report of speedy decision of EGFRi-induced pores and skin situations utilizing HT-001,” added Knie. “Because the examine progresses, we anticipate additional validating these outcomes and are excited in regards to the potential affect HT-001 might have on affected person outcomes.”
Final month, Hoth Therapeutics entered into an unique patent license settlement with the U.S. Division of Veterans Affairs (VA).
Below the phrases of the settlement, Hoth Therapeutics may have unique rights to develop, market, and commercialize merchandise and processes derived from the licensed patents.
The VA and Emory College have granted Hoth this license to develop the know-how additional.
Value Motion: HOTH inventory is up 246.5% at $2.84 finally verify Tuesday.
Learn Subsequent:
Photograph: Shutterstock
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
